Complex Diseases Require Multiple Routes of Attack

IMV’s current clinical strategy focuses on combination immuno-oncology therapies incorporating our lead therapeutic cancer vaccine, DPX-Survivac, for advanced ovarian cancer and diffuse large B-cell lymphoma (DLBCL). Both of these tumor types are associated with poor outcomes and are thus high unmet medical needs.

We are currently engaged in two triple-combination immunotherapy trials leveraging DPX-Survivac and metronomic cyclophosphamide with leading immuno-modulators in advanced ovarian cancer:

  • Incyte’s investigational IDO1 inhibitor, epacadostat
  • Merck’s currently marketed anti-PD-1 drug, pembrolizumab

Our clinical program focuses on broadening the utility of next-generation immunotherapies among patient populations with few treatment options.

Our goal with these programs is to confirm preliminary observations that DPX-Survivac may increase the vulnerability of these hard-to-treat tumors, while improving the utility of anti-cancer activity of these advanced agents.

Early clinical investigation of a second agent, DPX-E7, in human papillomavirus (HPV) cervical cancer is being pursued in an academic collaboration led by the Dana-Farber Cancer Institute.

Our ongoing clinical trials currently include:

Recurrent Ovarian Cancer
Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
ClinicalTrials.gov listing

Recurrent Survivin-Expressing DLBCL
Phase 2 Study of DPX-Survivac Vaccine, Pembrolizumab and Cyclophosphamide in Patients With Recurrent Survivin-Expressing DLBCL
ClinicalTrials.gov listing

Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
ClinicalTrials.gov listing

Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
ClinicalTrials.gov listing

High Standards. Even Higher Aspirations.

Working at IMV brings you to the forefront of cutting-edge science and research for cancer and other serious diseases. We’ve worked hard to build a culture of innovation and collaboration.

Learn more about life at IMV